Analysts Raise Rani Therapeutics Price Target Following Chugai Deal and Valuation Update

Analysts have increased their price target for Rani Therapeutics Holdings from $7.75 to $9.00. They cite recalibrated growth projections and adjusted profit expectations as key factors behind the change.

Rani Therapeutics Holdings’ lower future P/E and declining net profit margin highlight reduced growth expectations, which is reflected in the consensus price target holding steady at $7.75. What's in the News Filed a $2.99 million follow-on equity offering via registered direct offering, including Class A common stock and pre-funded warrants at significant discount.

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.3%.

AnalystConsensusTarget has decreased revenue growth from 152.5% to 129.8%, increased future PE multiple from 170.2x to 323.1x and decreased shares outstanding growth rate from 0.1% to 0.1%.